SecBot

SecBot
Nasdaq· CIK 0002096997

KLRA

Kailera Therapeutics, Inc.
$10.39 ▼ -5.80%
Prev close $11.03
Market cap$1.5B
12-mo target$42.40 (+308.1%)
Insider Buying Cluster (5 insiders)High Impact Filing (9/10)14 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on KLRA right now — valuation, ownership and activity at a glance.
Market Cap
$1.5B
Cap Size
Small Cap
Inst. Holders
50 funds
Inst. Value
$1.1B
Inst. Activity
14 buys / 0 sells
Insider Activity
$326.8M buy / $0.00 sell
Insider Net $
$326.8M
Social Sentiment
67° Warm
SEC Reports
20
Press Releases
3
Price chart 30d -34.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 fda
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Kailera announced Phase 1 data for ribupatide injection at EASD.
Sep 10, 2026 SEC
Nur Nicholson, newly appointed Chief Technology Officer of Kailera Therapeutics, filed a Form 3 initial statement of ben
3 — Impact 1/10
Sep 7, 2026 Insider
Nicholson Nur was granted 220,000 shares
Chief Technology Officer
Aug 12, 2026 SEC
Kailera Therapeutics reported Q2 2026 financial results, highlighting a net loss of $111.3M, a cash position of $1.17B t
8-K — Impact 4/10
Aug 1, 2026 SEC
Kailera Therapeutics (KLRA) filed a lawsuit against Structure Therapeutics, Inc. in the Northern District of California.
COURT-RULING — Impact 1/10
Jul 31, 2026 Event
Kailera Therapeutics, Inc. v. Structure Therapeutics, Inc. et al
Court ruling (cand) — Docket: 3:26-mc-80216
Jul 6, 2026 Insider
Tregoning Kathleen was granted 175,000 shares
See Remarks
Jun 30, 2026 Inst.
RTW INVESTMENTS, LP — NEW
10,776,820 shares ($237.4M)
Analyst ratings buy % +3.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
DateFirmActionRatingFirm rating
May 12, 2026Leerink PartnersINITIATEOutperform 49%
May 12, 2026JefferiesINITIATEBuy 53%
May 12, 2026Evercore ISI GroupINITIATEOutperform 59%
May 12, 2026JP MorganINITIATEOverweight 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20265610092%
Aug 1, 20265610092%
Jul 1, 20264510090%
Jun 1, 20263510089%
Price targets
Where 5 covering analysts think KLRA trades over the next 12 months.
$42.40 +308.1% upside Strong Buy
Current$10.39 Low$30.00 Median$41.00 High$57.00 5 analysts
$30.00$57.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
2 mentions 2 bullish 0 bearish 0 neutral
Recent posts
stocks Bullish 5mo ago
Biggest insider buys this week
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 5 bullish, 0 bearish, 0 mixed, 15 neutral · avg impact 4.3/10.Plus 3 press releases.
NEUTRAL31/10
Nur Nicholson, newly appointed Chief Technology Officer of Kailera Therapeutics, filed a Form 3 init
Sep 10, 2026
NEUTRAL8-K4/10
Kailera Therapeutics reported Q2 2026 financial results, highlighting a net loss of $111.3M, a cash
Aug 12, 2026
NEUTRALCOURT-RULING1/10
Kailera Therapeutics (KLRA) filed a lawsuit against Structure Therapeutics, Inc. in the Northern Dis
Aug 1, 2026
NEUTRALCOURT-RULING1/10
A federal magistrate judge granted a routine pro hac vice motion for an out-of-state attorney to rep
Jul 25, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
fda
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Kailera announced Phase 1 data for ribupatide injection at EASD.
Oct 1, 2026
short_volume
Short Volume: KLRA — 55.9% short (0.6M / 1.1M)
Short: 615,878 | Exempt: 0 | TRF Vol: 1,102,360 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
fda
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Kailera today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program.
Sep 28, 2026
short_volume
Short Volume: KLRA — 62.2% short (0.4M / 0.7M)
Short: 449,507 | Exempt: 0 | TRF Vol: 722,846 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: KLRA — 73.4% short (0.4M / 0.5M)
Short: 369,692 | Exempt: 0 | TRF Vol: 503,582 | Short Ratio: 73.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-1.01$-1.30–$-0.79—+5.1%1↑ 1↓$0.0B5
Next Q$-1.16$-1.54–$-0.95—+4.3%1↑ 1↓$0.0B5
Current FY$-4.10$-5.86–$-2.96—+6.5%0↑ 2↓$0.0B5
Next FY$-4.30$-5.89–$-2.99-4.9%+0.0%1↑ 1↓$0.0B5
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-1.011—
7d ago$-1.011—
30d ago$-1.065+0.054
60d ago$-0.925-0.086
90d ago$-0.890-0.121
Institutional ownership
Which big funds own KLRA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.1B total value (48,844,753 shares) as of 2026-Q2. Top holders: RTW, CANADA, FMR. Net buying activity: 14 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
RTW INVESTMENTS, LP10,776,820$237.4M22.1%NEW
CANADA PENSION PLAN INVESTMENT BOARD7,304,688$160.9M15.0%NEW
FMR LLC3,970,865$87.5M8.1%NEW
BlackRock, Inc.3,928,604$86.5M8.0%NEW
CITADEL ADVISORS LLC3,240,787$71.4M6.6%NEW
ADAGE CAPITAL PARTNERS GP, L.L.C.3,208,286$70.7M6.6%NEW
WELLINGTON MANAGEMENT GROUP LLP2,919,110$64.3M6.0%NEW
VANGUARD CAPITAL MANAGEMENT LLC1,693,958$37.3M3.5%NEW
VANGUARD PORTFOLIO MANAGEMENT LLC1,652,507$36.4M3.4%NEW
GEODE CAPITAL MANAGEMENT, LLC1,133,115$25.0M2.3%NEW
Recent position changes
FundActionPrevCurrentChangeValue
RTW INVESTMENTS, LPNEW—10,776,820—$237.4M
CANADA PENSION PLAN INVESTMENT BOARDNEW—7,304,688—$160.9M
FMR LLCNEW—3,970,865—$87.5M
BlackRock, Inc.NEW—3,928,604—$86.5M
CITADEL ADVISORS LLCNEW—3,240,787—$71.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW—3,208,286—$70.7M
WELLINGTON MANAGEMENT GROUP LLPNEW—2,919,110—$64.3M
VANGUARD CAPITAL MANAGEMENT LLCNEW—1,693,958—$37.3M
VANGUARD PORTFOLIO MANAGEMENT LLCNEW—1,652,507—$36.4M
GEODE CAPITAL MANAGEMENT, LLCNEW—1,133,115—$25.0M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
19 insiders, 40 transactions. Net $326.8M — $326.8M bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Sep 7, 2026Nicholson NurChief Technology OfficerAWARD220,000——
Jul 6, 2026Tregoning KathleenSee RemarksAWARD175,000——
Jun 9, 2026Renaud Ronald C JRCEO & PresidentEXERCISE38,094$5.25$200.0K
Apr 20, 2026Kaplan Andrew T.DirectorCONVERT17,857,143——
Apr 20, 2026Kaplan Andrew T.DirectorBUY8,398,438$16.00$134.4M
Apr 20, 2026Kaplan Andrew T.DirectorCONVERT17,857,143——
Apr 20, 2026Bain Capital Life Sciences Investors, LLC10%+ OwnerCONVERT16,875,000——
Apr 20, 2026Bain Capital Life Sciences Investors, LLC10%+ OwnerBUY1,562,500$16.00$25.0M
Apr 20, 2026Bain Capital Life Sciences Investors, LLC10%+ OwnerCONVERT16,875,000——
Apr 20, 2026Bain Capital Life Sciences Investors, LLC10%+ OwnerCONVERT4,145,768——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KLRA.
Shares short
5,962,752
Settlement Sep 15, 2026
Change vs prior
+5.3%
Semi-monthly cycle
Days to cover
7.6
At avg daily volume
Of shares outstanding
≈4.6%
Estimate — not % of float
All KLRA filing & press-release reports (29)